ARTICLE | Clinical News
Krystexxa pegloticase regulatory update
May 30, 2011 7:00 AM UTC
EMA accepted to review an MAA for Savient's Krystexxa pegloticase to treat chronic gout in patients refractory to conventional therapy. The pegylated urate oxidase is already marketed for the indicati...